Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–Goutières syndrome
- 20 August 2021
- journal article
- research article
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 64 (2) , 266-271
Abstract
Janus kinase (JAK) 1 inhibition represents a precision medicine approach in the treatment of Aicardi–Goutières syndrome (AGS), through targeting of type I interferon‐mediated cell signalling. Blood interferon mRNAseq has been proposed as a biomarker of disease with utility in therapeutic monitoring. Objective cerebrospinal fluid (CSF) biomarkers tracking treatment efficacy are currently lacking. Here, we report a retrospective case series of 13 patients (median age 6y, range 2y 6mo–17y; five females, eight males) with AGS demonstrating significantly elevated CSF neopterin levels at first sampling (median 200nmol/L, range 45–2024nmol/L), compared to 13 age‐matched controls with non‐inflammatory neurological conditions (median 23nmol/L, range 5–34nmol/L, pp=0.047). Our data indicate a biological effect of JAK inhibitors, and the potential role of CSF neopterin as a biomarker of treatment response.Keywords
Funding Information
- Cerebral Palsy Alliance Research Foundation
- Petre Foundation
This publication has 11 references indexed in Scilit:
- Janus Kinase Inhibition in the Aicardi–Goutières SyndromeNew England Journal of Medicine, 2020
- Treatments in Aicardi–Goutières syndromeDevelopmental Medicine & Child Neurology, 2019
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathiesJournal of Clinical Investigation, 2018
- An open-label trial of JAK 1/2 blockade in progressive IFIH1 -associated neuroinflammationNeurology, 2018
- Response to: ‘JAK inhibition in STING-associated interferonopathy’ by Crow et alAnnals of the Rheumatic Diseases, 2016
- Aicardi–Goutières syndrome and the type I interferonopathiesNature Reviews Immunology, 2015
- Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1American Journal of Medical Genetics Part A, 2015
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With MyelofibrosisMayo Clinic Proceedings, 2011
- Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammationDevelopmental Medicine & Child Neurology, 2009
- Clinical and Molecular Phenotype of Aicardi-Goutières SyndromeThe American Journal of Human Genetics, 2007